S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:STML - Stemline Therapeutics Stock Price, Forecast & News

$9.74
-0.20 (-2.01 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$9.65
Now: $9.74
$10.18
50-Day Range
$8.80
MA: $10.13
$10.99
52-Week Range
$7.82
Now: $9.74
$18.22
Volume406,187 shs
Average Volume613,687 shs
Market Capitalization$488.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STML
CUSIPN/A
Phone646-502-2311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.32 per share

Profitability

Net Income$-85,020,000.00

Miscellaneous

Employees92
Market Cap$488.26 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive STML News and Ratings via Email

Sign-up to receive the latest news and ratings for STML and its competitors with MarketBeat's FREE daily newsletter.


Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) issued its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million. View Stemline Therapeutics' Earnings History.

When is Stemline Therapeutics' next earnings date?

Stemline Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Stemline Therapeutics.

What price target have analysts set for STML?

7 brokers have issued 12-month price objectives for Stemline Therapeutics' stock. Their forecasts range from $17.00 to $35.00. On average, they expect Stemline Therapeutics' share price to reach $24.50 in the next year. This suggests a possible upside of 151.5% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.

What is the consensus analysts' recommendation for Stemline Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.

What are Wall Street analysts saying about Stemline Therapeutics stock?

Here are some recent quotes from research analysts about Stemline Therapeutics stock:
  • 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (10/30/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively." (1/25/2019)

Has Stemline Therapeutics been receiving favorable news coverage?

News headlines about STML stock have been trending somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Stemline Therapeutics.

Are investors shorting Stemline Therapeutics?

Stemline Therapeutics saw a decline in short interest in the month of November. As of November 29th, there was short interest totalling 4,880,000 shares, a decline of 21.7% from the November 14th total of 6,230,000 shares. Based on an average trading volume of 633,100 shares, the short-interest ratio is currently 7.7 days. Approximately 12.0% of the shares of the stock are sold short. View Stemline Therapeutics' Current Options Chain.

Who are some of Stemline Therapeutics' key competitors?

What other stocks do shareholders of Stemline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Viking Therapeutics (VKTX), Progenics Pharmaceuticals (PGNX), Syndax Pharmaceuticals (SNDX), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), FireEye (FEYE) and Gilead Sciences (GILD).

Who are Stemline Therapeutics' key executives?

Stemline Therapeutics' management team includes the folowing people:
  • Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
  • Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
  • Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
  • Mr. Robert Francomano, Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno, Sr. VP of Quality & Operations

Who are Stemline Therapeutics' major shareholders?

Stemline Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Eventide Asset Management LLC (8.30%), State Street Corp (4.01%), C WorldWide Group Holding A S (2.27%), Millennium Management LLC (1.58%), Empire Life Investments Inc. (1.17%) and Rhenman & Partners Asset Management AB (1.16%). Company insiders that own Stemline Therapeutics stock include Alan S Forman, David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.

Which institutional investors are selling Stemline Therapeutics stock?

STML stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC and Barclays PLC. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.

Which institutional investors are buying Stemline Therapeutics stock?

STML stock was purchased by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, State Street Corp, Empire Life Investments Inc., C WorldWide Group Holding A S, Squarepoint Ops LLC, Clear Harbor Asset Management LLC, Rhenman & Partners Asset Management AB and California Public Employees Retirement System. View Insider Buying and Selling for Stemline Therapeutics.

How do I buy shares of Stemline Therapeutics?

Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $9.74.

How big of a company is Stemline Therapeutics?

Stemline Therapeutics has a market capitalization of $488.26 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.View Additional Information About Stemline Therapeutics.

What is Stemline Therapeutics' official website?

The official website for Stemline Therapeutics is http://www.stemline.com/.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]


MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  411 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Equal Weight Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel